Futura Medical plc (FAMDF)
USD 0.38
(0.0%)
USD 0.38
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.96 Million GBP | -1.34% |
| 2022 | -6.87 Million GBP | -17.13% |
| 2021 | -5.86 Million GBP | -100.33% |
| 2020 | -2.92 Million GBP | 73.77% |
| 2019 | -11.16 Million GBP | -53.63% |
| 2018 | -7.26 Million GBP | -49.64% |
| 2017 | -4.85 Million GBP | -6.63% |
| 2016 | -4.55 Million GBP | 25.55% |
| 2015 | -6.11 Million GBP | -73.44% |
| 2014 | -3.52 Million GBP | -39.32% |
| 2013 | -2.53 Million GBP | -3.08% |
| 2012 | -2.45 Million GBP | -17.0% |
| 2011 | -2.09 Million GBP | -57.11% |
| 2010 | -1.33 Million GBP | 12.45% |
| 2009 | -1.52 Million GBP | 29.84% |
| 2008 | -2.17 Million GBP | 17.11% |
| 2007 | -2.62 Million GBP | -24.42% |
| 2006 | -2.1 Million GBP | 10.48% |
| 2005 | -2.35 Million GBP | -49.49% |
| 2004 | -1.57 Million GBP | -4.51% |
| 2003 | -1.5 Million GBP | -16.36% |
| 2002 | -1.29 Million GBP | 3.5% |
| 2001 | -1.34 Million GBP | -242.6% |
| 2000 | -392 Thousand GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 409.85 Thousand GBP | 0.0% |
| 2024 Q1 | 409.85 Thousand GBP | 116.38% |
| 2023 Q1 | -979.53 Thousand GBP | 75.64% |
| 2023 Q3 | -2.5 Million GBP | -27.73% |
| 2023 Q4 | -2.5 Million GBP | 0.0% |
| 2023 FY | -6.96 Million GBP | -1.34% |
| 2023 Q2 | -1.95 Million GBP | -100.0% |
| 2022 Q4 | -4.02 Million GBP | -100.0% |
| 2022 Q2 | -2.84 Million GBP | -100.0% |
| 2022 Q1 | -1.42 Million GBP | 64.06% |
| 2022 FY | -6.87 Million GBP | -17.13% |
| 2022 Q3 | -2.01 Million GBP | 29.44% |
| 2021 Q3 | -1.98 Million GBP | -4.22% |
| 2021 Q2 | -1.9 Million GBP | -100.0% |
| 2021 FY | -5.86 Million GBP | -100.33% |
| 2021 Q1 | -950.94 Thousand GBP | 38.07% |
| 2021 Q4 | -3.96 Million GBP | -100.0% |
| 2020 Q2 | -1.39 Million GBP | -100.0% |
| 2020 Q3 | -767.76 Thousand GBP | 44.88% |
| 2020 FY | -2.92 Million GBP | 73.77% |
| 2020 Q4 | -1.53 Million GBP | -100.0% |
| 2020 Q1 | -696.43 Thousand GBP | 88.17% |
| 2019 Q3 | -2.94 Million GBP | 44.17% |
| 2019 FY | -11.16 Million GBP | -53.63% |
| 2019 Q1 | -2.63 Million GBP | -11.09% |
| 2019 Q2 | -5.27 Million GBP | -100.0% |
| 2019 Q4 | -5.88 Million GBP | -100.0% |
| 2018 Q3 | -2.37 Million GBP | -88.51% |
| 2018 FY | -7.26 Million GBP | -49.64% |
| 2018 Q2 | -1.25 Million GBP | 0.0% |
| 2018 Q1 | -1.25 Million GBP | 11.58% |
| 2018 Q4 | -2.37 Million GBP | 0.0% |
| 2017 Q2 | -1 Million GBP | 0.0% |
| 2017 Q1 | -1 Million GBP | 12.22% |
| 2017 Q4 | -1.42 Million GBP | 0.0% |
| 2017 FY | -4.85 Million GBP | -6.63% |
| 2017 Q3 | -1.42 Million GBP | -41.92% |
| 2016 Q1 | -1.13 Million GBP | 26.74% |
| 2016 FY | -4.55 Million GBP | 25.55% |
| 2016 Q3 | -1.14 Million GBP | -0.86% |
| 2016 Q2 | -1.13 Million GBP | 0.0% |
| 2016 Q4 | -1.14 Million GBP | 0.0% |
| 2015 Q1 | -1.51 Million GBP | -61.17% |
| 2015 Q2 | -1.51 Million GBP | 0.0% |
| 2015 Q4 | -1.54 Million GBP | 0.0% |
| 2015 Q3 | -1.54 Million GBP | -2.4% |
| 2015 FY | -6.11 Million GBP | -73.44% |
| 2014 Q2 | -825.88 Thousand GBP | 0.0% |
| 2014 Q3 | -937.52 Thousand GBP | -13.52% |
| 2014 FY | -3.52 Million GBP | -39.32% |
| 2014 Q4 | -937.52 Thousand GBP | 0.0% |
| 2014 Q1 | -825.88 Thousand GBP | -10.57% |
| 2013 Q3 | -746.92 Thousand GBP | -43.96% |
| 2013 Q2 | -518.85 Thousand GBP | 0.0% |
| 2013 Q1 | -518.85 Thousand GBP | 0.0% |
| 2013 FY | -2.53 Million GBP | -3.08% |
| 2013 Q4 | -746.92 Thousand GBP | 0.0% |
| 2012 FY | -2.45 Million GBP | -17.0% |
| 2011 FY | -2.09 Million GBP | -57.11% |
| 2010 FY | -1.33 Million GBP | 12.45% |
| 2009 FY | -1.52 Million GBP | 29.84% |
| 2008 FY | -2.17 Million GBP | 17.11% |
| 2007 FY | -2.62 Million GBP | -24.42% |
| 2006 FY | -2.1 Million GBP | 10.48% |
| 2005 FY | -2.35 Million GBP | -49.49% |
| 2004 FY | -1.57 Million GBP | -4.51% |
| 2003 FY | -1.5 Million GBP | -16.36% |
| 2002 FY | -1.29 Million GBP | 3.5% |
| 2001 FY | -1.34 Million GBP | -242.6% |
| 2000 FY | -392 Thousand GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 90.299% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 241.689% |
| SQZ Biotechnologies Company | -75.82 Million USD | 90.816% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 60.981% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 108.508% |
| Mesoblast Limited | -84.14 Million USD | 91.724% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -353.356% |
| Genus plc | 6.4 Million USD | 208.809% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 171.479% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -647.683% |
| Marizyme, Inc. | -34.08 Million USD | 79.57% |
| ContraFect Corporation | -56.88 Million USD | 87.759% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 16.602% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -52.891% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -396.706% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -144.299% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -153.151% |
| MultiCell Technologies, Inc. | -722.81 USD | -963330.224% |
| Accustem Sciences Inc. | -3.74 Million USD | -85.878% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 88.195% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1341.589% |
| Q BioMed Inc. | -3.44 Million USD | -102.105% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 296.717% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1687.553% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -165.032% |
| Biomind Labs Inc. | -1 Million USD | -589.753% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -42.714% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -4.75% |
| Skye Bioscience, Inc. | -13.67 Million USD | 49.065% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -250.558% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -23149.766% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -38.047% |
| IMV Inc. | -38.67 Million USD | 81.993% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 56.119% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -260.33% |
| GB Sciences, Inc. | -1.42 Million USD | -390.231% |
| Alpha Cognition Inc. | -9.7 Million USD | 28.25% |
| HST Global, Inc. | -140.9 Thousand USD | -4842.104% |
| CSL Limited | 3.7 Billion USD | 100.188% |
| Halberd Corporation | -75.05 Thousand USD | -9178.841% |
| Enzolytics Inc. | -2.14 Million USD | -224.077% |
| Resverlogix Corp. | -12.74 Million USD | 45.378% |
| Affymax, Inc. | -15.04 Million USD | 53.717% |
| SYBLEU INC | -149.18 Thousand USD | -4568.032% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -119.797% |
| argenx SE | -425.04 Million USD | 98.362% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 87.454% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -567.028% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -340.925% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -104.517% |
| AVAX Technologies, Inc. | 6.69 Million USD | 204.047% |
| Zenith Capital Corp. | -8.94 Million USD | 22.132% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.325% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -39873.423% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -183.62% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -3960.281% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 87.332% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -140.027% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -607.662% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -273.519% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -454.44% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -247.362% |
| BioStem Technologies, Inc. | -7.77 Million USD | 10.48% |
| ONE Bio Corp. | 13.68 Million USD | 150.899% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -3737.105% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -421.462% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -519.054% |
| Agentix Corp. | -1.37 Million USD | -407.654% |
| LadRx Corporation | -3.82 Million USD | -82.125% |
| Cell Source, Inc. | -4.32 Million USD | -60.999% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1576.082% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -913.723% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -913.723% |
| NovAccess Global Inc. | -2.46 Million USD | -182.304% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -138.531% |
| Itoco Inc. | -919.14 Thousand USD | -657.64% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -64.301% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -522.321% |
| Kadimastem Ltd | -3.04 Million USD | -129.053% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -2560.71% |
| CytoDyn Inc. | -18.05 Million USD | 61.437% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -27566.945% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1155.752% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3064.228% |
| Qrons Inc. | -643.67 Thousand USD | -981.873% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1133.13% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -212.294% |
| Rebus Holdings, Inc. | -664 Thousand USD | -948.761% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -283.4% |
| International Stem Cell Corporation | -663 Thousand USD | -950.342% |
| Bioxytran, Inc. | -3.82 Million USD | -82.291% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -13129.046% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -34136.824% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 80.798% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -330.394% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -846.377% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -123.843% |
| Neutra Corp. | -229.48 Thousand USD | -2934.508% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 60.296% |
| PureTech Health plc | -146.19 Million USD | 95.237% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 67.597% |
| IXICO plc | -1.43 Million USD | -384.605% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 26.628% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 94.283% |
| CSL Limited | 3.81 Billion USD | 100.183% |
| Cellectis S.A. | -108.85 Million USD | 93.603% |